Company Overview

Oramed Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on the development of oral drug delivery platforms for peptide-based therapeutics, particularly insulin and other protein-based drugs that are traditionally administered by injection. The company operates within the biopharmaceutical and diabetes-treatment industries and has historically centered its research on oral formulations intended to improve patient compliance and expand accessibility for chronic disease management. Its core technology platform is designed to protect protein-based drugs from degradation in the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s primary business activities have included development of oral insulin capsule candidates and related delivery technologies. Oramed has also expanded its strategic focus beyond therapeutic development through investments and corporate transactions tied to biotechnology and healthcare-related opportunities. Founded in 2006 and headquartered in Jerusalem, Israel, the company evolved from an early-stage drug delivery research venture into a Nasdaq-listed biotechnology company. Public filings and investor materials indicate that Oramed’s positioning has relied on proprietary oral delivery technology, intellectual property protections, and partnerships aimed at advancing clinical development and commercialization opportunities.

Business Operations

Oramed generates value primarily through research and development activities tied to its proprietary oral protein delivery technology platform and related intellectual property. Historically, the company’s lead programs included oral insulin capsule candidates developed for diabetes treatment. The company has also explored oral delivery applications for additional peptide therapeutics. Revenue generation has been limited relative to commercial-stage pharmaceutical companies, with financial disclosures showing that operations have primarily been funded through equity offerings, investments, licensing activity, and strategic transactions rather than recurring product sales.

The company operates through biotechnology development activities in both Israel and the United States, with research oversight, clinical coordination, and corporate functions spanning multiple jurisdictions. Oramed has controlled intellectual property associated with oral delivery mechanisms and formulation technologies. Public disclosures have also referenced collaborations with contract research organizations, manufacturing partners, and healthcare-related entities supporting clinical development and regulatory activities. Data regarding certain operational partnerships and commercialization arrangements is limited or subject to change based on available public sources.

Strategic Position & Investments

Oramed’s strategic direction has combined biotechnology platform development with broader healthcare-related investment activity. In recent years, the company became associated with investment activity involving Scilex Holding Company, reflecting a diversification strategy beyond its original oral insulin focus. Company disclosures and regulatory filings indicate that management has pursued opportunities intended to enhance shareholder value through strategic investments, structured transactions, and healthcare-sector exposure alongside continued biotechnology development efforts.

The company’s long-term initiatives have included advancing oral drug delivery technologies, preserving and expanding intellectual property assets, and evaluating acquisition or investment opportunities within the healthcare and life sciences sectors. Oramed has emphasized the potential applicability of its delivery platform to additional therapeutic categories involving peptide-based medicines. While the company continues to maintain biotechnology development operations, public information suggests that strategic capital allocation and investment-related activities have become increasingly important components of its corporate strategy. Some future commercialization pathways and pipeline priorities remain subject to clinical, regulatory, and financial outcomes.

Geographic Footprint

Oramed is headquartered in Jerusalem, Israel, and maintains operational and corporate ties to the United States through its Nasdaq listing, investor relations activities, and participation in U.S. capital markets. Its business activities have historically involved clinical and regulatory engagement across multiple international regions, including collaboration with research institutions and development partners connected to diabetes and biotechnology markets.

The company’s market presence has primarily been concentrated in North America, Israel, and selected international healthcare markets tied to clinical development opportunities. Its investor base and regulatory reporting obligations are significantly connected to the United States, including filings with the U.S. Securities and Exchange Commission (SEC). Publicly available information indicates that Oramed’s operational influence remains more research- and investment-oriented rather than driven by large-scale commercial pharmaceutical distribution infrastructure.

Leadership & Governance

Oramed was founded by researchers associated with oral insulin and protein delivery technology development, including scientific leadership connected to the company’s early formulation work. The company operates under a governance structure typical of publicly traded biotechnology firms, with executive management overseeing clinical strategy, corporate finance, regulatory matters, and investment activities. Leadership communications have emphasized technology innovation, shareholder value creation, and strategic flexibility in biotechnology and healthcare investments.

Key executives and leadership figures identified in recent public filings include:

• Nadav Kidron – Chief Executive Officer
• Miriam Kidron – Chief Scientific Officer
• Josh Hexter – Chief Operating Officer and Chief Financial Officer
• Ron Mayron – Chairman of the Board

The company’s leadership strategy has focused on advancing proprietary oral delivery technologies while evaluating broader strategic opportunities within healthcare and biotechnology markets. Governance and operational disclosures are primarily documented through SEC filings, annual reports, and investor communications.